Constellation Pharmaceuticals (NASDAQ:CNST) versus Acerus Pharmaceuticals (NASDAQ:ASPCF) Financial Analysis

Constellation Pharmaceuticals (NASDAQ:CNST) and Acerus Pharmaceuticals (OTCMKTS:ASPCF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Earnings and Valuation

This table compares Constellation Pharmaceuticals and Acerus Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Constellation Pharmaceuticals N/A N/A -$85.55 million ($3.04) -10.82
Acerus Pharmaceuticals $3.77 million 2.43 -$16.13 million N/A N/A

Acerus Pharmaceuticals has higher revenue and earnings than Constellation Pharmaceuticals.

Institutional & Insider Ownership

93.0% of Constellation Pharmaceuticals shares are owned by institutional investors. 43.7% of Constellation Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Constellation Pharmaceuticals and Acerus Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Constellation Pharmaceuticals N/A -63.49% -46.02%
Acerus Pharmaceuticals -219.97% N/A -115.72%

Analyst Ratings

This is a summary of current recommendations for Constellation Pharmaceuticals and Acerus Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Constellation Pharmaceuticals 0 1 7 0 2.88
Acerus Pharmaceuticals 0 0 0 0 N/A

Constellation Pharmaceuticals currently has a consensus target price of $46.71, indicating a potential upside of 42.08%. Given Constellation Pharmaceuticals’ higher possible upside, analysts plainly believe Constellation Pharmaceuticals is more favorable than Acerus Pharmaceuticals.

Volatility and Risk

Constellation Pharmaceuticals has a beta of 5.85, indicating that its stock price is 485% more volatile than the S&P 500. Comparatively, Acerus Pharmaceuticals has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.

Summary

Constellation Pharmaceuticals beats Acerus Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.